tiprankstipranks
Trending News
More News >
AC Immune (ACIU)
:ACIU
US Market
Advertisement

AC Immune SA (ACIU) Stock Forecast & Price Target

Compare
511 Followers
See the Price Targets and Ratings of:

ACIU Analyst Ratings

Strong Buy
3Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
Based on 3 analysts giving stock ratings to
AC
Immune SA
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ACIU Stock 12 Month Forecast

Average Price Target

$10.00
▲(266.30% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for AC Immune SA in the last 3 months. The average price target is $10.00 with a high forecast of $12.00 and a low forecast of $8.00. The average price target represents a 266.30% change from the last price of $2.73.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.21,2.963076923076923,3.716153846153846,4.469230769230769,5.222307692307692,5.975384615384614,6.728461538461538,7.48153846153846,8.234615384615385,8.987692307692306,9.74076923076923,10.493846153846153,11.246923076923075,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.21,2.809230769230769,3.4084615384615384,4.007692307692308,4.606923076923077,5.206153846153846,5.805384615384615,6.404615384615385,7.003846153846154,7.603076923076923,8.202307692307691,8.801538461538462,9.400769230769232,{"y":10,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.21,2.6553846153846155,3.100769230769231,3.546153846153846,3.9915384615384615,4.436923076923077,4.882307692307692,5.327692307692308,5.773076923076923,6.218461538461538,6.663846153846154,7.109230769230769,7.554615384615384,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.65,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.82,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.23,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.54,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.64,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.21,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$12.00Average Price Target$10.00Lowest Price Target$8.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG
$8
Buy
193.04%
Upside
Reiterated
09/08/25
AC Immune SA: Strategic Focus and Innovative Platforms Drive Buy Rating Amid Promising Immunotherapy Developments
Leerink Partners Analyst forecast on ACIU
Leerink Partners
Leerink Partners
Buy
Reiterated
09/04/25
Leerink Partners Reaffirms Their Buy Rating on AC Immune SA (ACIU)We understand the decision to restructure the company and refocus the pipeline, triggered by a more conservative stance for the timing of potential catalysts. Management indicated that it was reducing spending and increasing operational efficiency to focus on key programs focused on disease prevention that may reach important value- inflection milestones in the next 2 years. The company continues to have an attractive pipeline of assets and strong partnerships that keeps us patient with the name, and we reiterate our Outperform rating and PT of $9.
H.C. Wainwright Analyst forecast on ACIU
H.C. Wainwright
H.C. Wainwright
$12
Buy
339.56%
Upside
Reiterated
08/06/25
Analysts Are Bullish on These Healthcare Stocks: Merus (MRUS), AC Immune SA (ACIU)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG
$8
Buy
193.04%
Upside
Reiterated
09/08/25
AC Immune SA: Strategic Focus and Innovative Platforms Drive Buy Rating Amid Promising Immunotherapy Developments
Leerink Partners Analyst forecast on ACIU
Leerink Partners
Leerink Partners
Buy
Reiterated
09/04/25
Leerink Partners Reaffirms Their Buy Rating on AC Immune SA (ACIU)We understand the decision to restructure the company and refocus the pipeline, triggered by a more conservative stance for the timing of potential catalysts. Management indicated that it was reducing spending and increasing operational efficiency to focus on key programs focused on disease prevention that may reach important value- inflection milestones in the next 2 years. The company continues to have an attractive pipeline of assets and strong partnerships that keeps us patient with the name, and we reiterate our Outperform rating and PT of $9.
H.C. Wainwright Analyst forecast on ACIU
H.C. Wainwright
H.C. Wainwright
$12
Buy
339.56%
Upside
Reiterated
08/06/25
Analysts Are Bullish on These Healthcare Stocks: Merus (MRUS), AC Immune SA (ACIU)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AC Immune SA

1 Month
xxx
Success Rate
5/23 ratings generated profit
22%
Average Return
-3.86%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 21.74% of your transactions generating a profit, with an average return of -3.86% per trade.
3 Months
xxx
Success Rate
9/23 ratings generated profit
39%
Average Return
-3.37%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 39.13% of your transactions generating a profit, with an average return of -3.37% per trade.
1 Year
Marc GoodmanLeerink Partners
Success Rate
7/23 ratings generated profit
30%
Average Return
-17.44%
reiterated a buy rating 22 days ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 30.43% of your transactions generating a profit, with an average return of -17.44% per trade.
2 Years
xxx
Success Rate
8/23 ratings generated profit
35%
Average Return
-11.86%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 34.78% of your transactions generating a profit, with an average return of -11.86% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ACIU Analyst Recommendation Trends

Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
5
3
2
2
3
Buy
1
1
0
0
1
Hold
2
7
12
16
12
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
11
14
18
16
In the current month, ACIU has received 4 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. ACIU average Analyst price target in the past 3 months is 10.00.
Each month's total comprises the sum of three months' worth of ratings.

ACIU Financial Forecast

ACIU Earnings Forecast

Next quarter’s earnings estimate for ACIU is -$0.24 with a range of -$0.25 to -$0.21. The previous quarter’s EPS was -$0.26. ACIU beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.14% of the time in the same period. In the last calendar year ACIU has Outperformed its overall industry.
Next quarter’s earnings estimate for ACIU is -$0.24 with a range of -$0.25 to -$0.21. The previous quarter’s EPS was -$0.26. ACIU beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.14% of the time in the same period. In the last calendar year ACIU has Outperformed its overall industry.

ACIU Sales Forecast

Next quarter’s sales forecast for ACIU is $998.90K with a range of $0.00 to $1.86M. The previous quarter’s sales results were $1.58M. ACIU beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year ACIU has Outperformed its overall industry.
Next quarter’s sales forecast for ACIU is $998.90K with a range of $0.00 to $1.86M. The previous quarter’s sales results were $1.58M. ACIU beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year ACIU has Outperformed its overall industry.

ACIU Stock Forecast FAQ

What is ACIU’s average 12-month price target, according to analysts?
Based on analyst ratings, AC Immune’s 12-month average price target is 10.00.
    What is ACIU’s upside potential, based on the analysts’ average price target?
    AC Immune has 266.30% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ACIU a Buy, Sell or Hold?
          AC Immune has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
            What is AC Immune’s price target?
            The average price target for AC Immune is 10.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $12.00 ,the lowest forecast is $8.00. The average price target represents 266.30% Increase from the current price of $2.73.
              What do analysts say about AC Immune?
              AC Immune’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of ACIU?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis